MicroBlate™ Flex exceeds 100 clinical cases

Creo’s milestone is real, but the investment case remains unproven and mostly hype-driven.

What the company is saying

Creo Medical Group plc is positioning itself as a leader in minimally invasive cancer treatment, highlighting the completion of over 100 clinical cases using its MicroBlate™ Flex microwave ablation device. The company’s core narrative is that this milestone demonstrates growing clinical adoption, procedural expertise, and confidence among leading UK and European centres. Management frames the announcement as a pivotal step in the broader rollout of MicroBlate™ Flex, especially following its use in lung tumour procedures. The language is assertive and optimistic, repeatedly emphasizing the device’s potential to transform treatment pathways for hard-to-reach lesions and early-stage lung cancer. Claims about the device’s precision, suitability for minimally invasive procedures, and integration with robotic-assisted workflows are presented as differentiators, though without supporting data. The announcement heavily leans on forward-looking statements, such as expectations for rapid case growth over the next 12 months and management’s belief in a significant addressable market. Notably, the company references an ongoing collaboration with Intuitive Surgical, Inc., but provides no details or evidence of commercial impact from this partnership. Among notable individuals, Craig Gulliford (CEO) is the primary spokesperson, lending institutional credibility, while Professor Pallav Shar is cited as a clinical expert, which may reassure some investors about medical validation. Overall, the communication style is promotional, aiming to build investor excitement around clinical momentum and future market potential, but it omits any discussion of financial performance, commercialisation timelines, or regulatory hurdles.

What the data suggests

The only concrete data disclosed is that more than 100 clinical cases have been completed with MicroBlate™ Flex as of 23 July 2026. There are no financial figures—no revenue, profit, cash flow, or cost data—provided in the announcement. This means the financial trajectory of the company, or even of the MicroBlate™ Flex product line, cannot be assessed from this release. The gap between what is claimed and what is evidenced is substantial: while the company asserts growing adoption, procedural expertise, and market opportunity, the only substantiated fact is the number of cases performed. There is no information on whether these cases were part of paid commercial use, clinical trials, or compassionate access, nor any indication of repeat usage, customer retention, or geographic spread. No prior targets or guidance are referenced, so it is impossible to determine if the company is meeting, exceeding, or missing its own benchmarks. The quality of disclosure is poor from a financial analysis perspective, as key metrics such as sales, margins, or even the number of active clinical sites are missing. An independent analyst would conclude that, while the clinical milestone is a positive signal of some real-world use, the lack of financial and operational transparency makes it impossible to judge the commercial significance or sustainability of this progress.

Analysis

The announcement is upbeat, highlighting the completion of over 100 clinical cases with MicroBlate™ Flex, which is a tangible milestone. However, the majority of the claims are forward-looking or qualitative, such as expectations for rapid case growth, significant market potential, and ongoing clinical evidence generation. There is no disclosure of financial metrics (revenue, profit, margins), so the true business impact cannot be assessed. The language inflates the significance of the milestone by linking it to broader clinical adoption and market opportunity without supporting data. The only realised, measurable progress is the number of clinical cases completed. The rest of the narrative is aspirational or descriptive, lacking quantitative evidence for claims about expertise, confidence, or market size.

Risk flags

• ●Lack of financial disclosure is a major risk: the announcement provides no revenue, margin, or cost data, making it impossible to assess commercial traction or financial health. Investors are left to speculate about the business impact of the clinical milestone.
• ●Overreliance on forward-looking statements: the majority of claims are about future growth, market size, and clinical adoption, none of which are substantiated by current data. This pattern increases the risk of disappointment if projections are not met.
• ●No evidence of commercial adoption: while over 100 clinical cases have been completed, there is no information on whether these were paid procedures, part of trials, or free-of-charge, so the revenue impact could be negligible.
• ●Absence of operational metrics: the company does not disclose the number of active clinical sites, repeat usage rates, or geographic distribution, making it difficult to gauge the depth and breadth of adoption.
• ●Execution risk is high: the path from clinical milestone to widespread commercial adoption involves regulatory, reimbursement, and competitive hurdles, none of which are addressed in the announcement.
• ●Collaboration with Intuitive Surgical is mentioned but not quantified: without details on the scope, financial terms, or deliverables, investors cannot assess the real value or risk of this partnership.
• ●Potential for hype-driven volatility: the promotional tone and lack of hard data may attract speculative interest, increasing share price volatility without underlying business progress.
• ●Timeline risk: claims about rapid growth and significant market opportunity are not tied to specific, measurable milestones, making it easy for management to shift goalposts or delay delivery without accountability.

Bottom line

For investors, this announcement signals that Creo Medical’s MicroBlate™ Flex device is being used in real-world clinical settings, with over 100 cases completed—a genuine, if modest, milestone. However, the absence of any financial data or operational metrics means there is no way to assess whether this clinical adoption is translating into meaningful revenue, profit, or market share. The company’s narrative is credible in terms of clinical progress, but the investment case is almost entirely aspirational, built on management’s projections and beliefs rather than hard evidence. The involvement of named clinical and executive figures lends some credibility, but does not guarantee commercial success or institutional backing. To change this assessment, Creo would need to disclose specific financial results attributable to MicroBlate™ Flex, details on paid versus trial usage, customer retention rates, and concrete milestones for commercial rollout. Investors should watch for future updates that include revenue figures, gross margins, number of active clinical sites, and regulatory or reimbursement wins. At this stage, the announcement is worth monitoring as an early signal of product traction, but it is not actionable as a standalone investment catalyst. The single most important takeaway is that clinical milestones are necessary but not sufficient—without financial transparency and operational detail, the investment case remains speculative and high risk.

Announcement summary

(AIM: CREO) Creo Medical Group plc announced that more than 100 clinical cases have now been completed using its MicroBlate™ Flex microwave ablation product. This milestone reflects increasing utilisation across leading centres in the UK and Europe and marks an important step in building procedural expertise and clinical confidence. The company previously announced the commencement of lung tumour procedures and is seeing increased use of the device in minimally invasive treatment pathways. MicroBlate™ Flex is designed to deliver precise, controlled ablation of nodules and tumours in several tissue types through a flexible endoscopic platform. Management believe the potential market size for MicroBlate™ Flex applications is significant. The company expects case numbers to rise rapidly over the next 12 months. Creo remains focused on expanding the clinical evidence base for MicroBlate™ Flex through ongoing clinical studies, post-market data generation, investigator-led research and scientific publications.

Disagree with this article?